Valneva Shares Gain After Positive Vaccine Trial Results
05 Décembre 2022 - 10:19AM
Dow Jones News
By Cecilia Butini
Shares in French pharmaceutical company Valneva SE rose in early
trading on Monday after the company reported positive data on its
vaccine against mosquito-borne viral disease Chikungunya.
At 0827 GMT, shares were up 8.5% at EUR7.32.
The vaccine data focused on persistence of antibodies against
Chikungunya after 12 months of receiving a shot, Valneva said. The
company also said it didn't identify any safety concerns around the
vaccine, confirming the safety profile established in previous
trials.
These positive results bode well for an upcoming Biologics
License Application with the U.S. Food and Drug Administration,
which is expected to be completed by year-end, Bryan Garnier
analysts said in a note.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 05, 2022 04:04 ET (09:04 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
